In Vivo Cancer Models

Noble Scientists have deep experience designing and implementing a variety of animal models to characterize oncology drug candidates for efficacy, pharmacodynamics, pharmacokinetics, toxicity and bioavailability.  Models include:

OncoDiversity™ Cell Line Panel

Noble will screen your drug candidates using our OncoDiversity Cell Line Panel, a diverse collection of cell lines spanning multiple cancer indications.

Results from the cell line panel screen can be matched to the genetic background in the cancer cell lines to determine a molecular biomarker profile correlating with the activity of your drug candidate.

Noble’s biobank resource containing DNA and protein from each cell line is then used to confirm the drug:biomarker correlations that were discovered in the cell panel screen.

Validation of the drug and biomarker response in vivo can be carried out in cell models shown to be sensitive to your drug.

These studies provide an understanding of the expression status of the target and molecular pathway in the selected model; determination of the active plasma concentrations of the drug; modulation of the downstream pathway in which the target functions; and assessment of the therapeutic index.

By examining the response of a broad spectrum of validated DNA and protein-based biomarkers to therapeutics, we deliver data that enable more confident decisions.


Live animal imaging with the Perkin Elmer IVIS system using bioluminescent or fluorescent reporters

Flow Cytometry

Next Generation Sequencing

Pharmacodynamic Models

Noble provides services for establishing pharmacodynamic biomarkers that link drug candidate activity affecting the molecular target with downstream signaling pathway effects.

Results provide a clear rational for determining optimal dose and schedule requirements for clinical studies.

Cancer Model Options

We offer transgenic, induced, or surgically modified animal models.  Tumor growth delaytumor growth inhibition, log10 cell kill, survivalcombination or adjuvant design approaches may be used to assess your compound for:

  • Drug potency (IC50) 
  • Apoptosis
  • Cell Cycle
  • Biomarker Discovery/Screening
  • Pathway Interrogation
  • Therapeutic Combinations
  • Tumor antigen testing
  • Flow Cytometry based Immunophenotyping and Cytokine Analysis
  • Real time tumor growth monitoring by Live animal Imaging

Proven Expertise

We have experience with a variety of mammalian species used for vaccine and drug development. Our studies range from single digit to hundreds of animals.

Our scientists, with over 15 years of GLP experience, provide all aspects of the GLP process from design to regulatory support of your IND, IDE or PMA FDA submission.